Allogeneic hematopoietic stem cell transplantation in 24 patients with β-thalassemia major
2011-08-15LiuRongrong刘容容DepyHematol1stHospGuangxiMedUnivNanning530021ChinOrganTransplant201132144147
Liu Rongrong(刘容容,Depy Hematol,1st Hosp,Guangxi Med Univ,Nanning 530021)…∥Chin J Organ Transplant.-2011,32(3).-144 ~147
Allogeneic hematopoietic stem cell transplantation in 24 patients with β-thalassemia major
Liu Rongrong(刘容容,Depy Hematol,1st Hosp,Guangxi Med Univ,Nanning 530021)…∥Chin J Organ Transplant.-2011,32(3).-144 ~147
ObjectiveTo investigate the effect of allgeneic hematopoietic stem cell transplantation(allo-HSCT)for β - thalassemia major.MethodsTwenty - four β -thalassemia major patients with median age of 4 years(range:2-15 years),18 boys and 6 girls,received allo-HSCT.They were classified into classⅡ -Ⅲ according to Pesaro thalassemia classification.Twentythree transplantations were from sibling donor and 1 was from mother,either HLA -identical(n=23)or HLA -mismatched(5/6)(n=1).Fifteen patients received bone marrow transplantation(BMT)plus peripheral blood stem cell transplantation(PBSCT),and 9 were subjected to umbilical cord blood transplantation(UCBT).The conditioning regimen consisted of busalphan,cyclophosphamide,fludarabine,plus hydroxyurea before transplantation.Graft-versus-host disease(GVHD)prophylaxis included CsA,methotrexate,antilymphpcute globulin,and mycophenolate mofetil.The median follow-up period was 13 months(range:3 -69).ResultsOf 24 patients,there were 21 cases(87.5%)of disease-free survival,1(4.2%)transplantation - related death,and 2 cases(8.3%)of rejection.Three-year overall survival and disease-free survival rate was 91.7%and 87.5%,respectively.The cumulative incidence of gradeⅡ-Ⅳacute GVHD and chronic GVHD was 16.7 and 20.3%,particularly cumulative extensive chronic GVHD was 5.0%.ConclusionThe sibling donor BMT plus PBSCT is an effective and safe way to treat β - thalassemia major.Cord blood is an important source of hematopoietic stem cells for HSCT.The protocol GVHD prophylaxis of CsA,MTX,ATG with a low-dose and short course of MMF can effectively reduce the incidence of severe acute GVHD,improve the outcome of thalassemia transplantation.12 refs,1 fig,1 tab.
(Authors)
杂志排行
外科研究与新技术的其它文章
- Length of warm ischemic tolerance for epithelial regeneration in heterotopic rat tracheal isog-rafts
- Expression of bradykinin as a substrate of CD26/DPP IV in rats ischemia/reperfusion injury following lung transplantation
- Apoptosis and oxidative injury of donor islets during isolatio
- Efficacy of rituximab-containing regimens on post-transplantation lymphoproliferative disorder following haploidentical hematopoietic stem cell trans-plantatio: reor f 3 css
- Ailogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 yers of g
- Clinical analysis of 100 cases of lung transplantation for end-stage palmonary disease